Suppression of inflammatory and neuropathic pain by uncoupling collapsin response mediator protein 2 (CRMP-2) from the presynaptic calcium channel complex

Rajeev Khanna 2,3,4,6 and M Britton 1,4,6,7. Sarah M Wilson 1,5,6,7, Caroline Balla 1,2,3,4,6, and Philip L Johnson 1,5,6,7, John V Watkins 1,2,3,4,6, Matthew S Rabin 2,3,4,6, Yiming Wang 1,2,3,4,6, Jonathan Feigen 1,5,6,7, May Kurihara 1,2,3,4,6, Nikola S Brudovec 1,2,3,4,6, Russell J Dohy 4,6,7, and Fletcher J White 1,4,6,7.

1. Program in Medical Neurosciences, Paul and Galen Skaggs Neurosciences Research Institute, 2. Department of Pharmacology and Toxicology, 3. Department of Biochemistry and Molecular Biology, 4. Department of Psychology, 5. Department of Neurological Surgery, 6. Department of Anatomy and Cell Biology, 7. Department of Anesthesiology, Indiana University School of Medicine, Indianapolis, Indiana, USA, 8. Memory Function Laboratory, Pain Research Center, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA, 9. Department of Neurology, 10. Department of Indiana Clinical and Translational Sciences Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Introduction

Objective

Introducing... TAT-CBD3

in vivo Pain Models: Inflammatory Pain

in vivo Pain Models: Neuropathic

Searching for side effects

In vivo Pain Models: Headache-associated pain

Summary

Uptake into DRGs 15 min following i.p. injection of FITC-TAT-CBD3

Test to verify efficacy

Efficient transduction into DRGs

TAT-CBD3 injection into hindpaw 2.5% Formalin Inj. Mesause Number of Flinches 30 minutes

Develop peptide to interfere with CaV2.2-CRMP-2 interaction Test

CGRP Release